PT886
- Generic Name
- PT886
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
PT886 is a bispecific antibody against Claudin 18.2 and cluster of differentiation 47 (CD47)
- Associated Conditions
- -
- Associated Therapies
- -
PT886 for Treatment of Patients with Metastatic/Advanced Gastric, Gastroesophageal Junction and Pancreatic Adenocarcinoma (the TWINPEAK Study)
- First Posted Date
- 2022-08-01
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Phanes Therapeutics
- Target Recruit Count
- 135
- Registration Number
- NCT05482893
- Locations
- 🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Sarah Cannon Research Institute (SCRI), Denver, Colorado, United States
🇺🇸Dana-Farber Cancer Institute (DFCI), Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath